Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
Official_Bellicum_Logo_RGB.jpg
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
September 01, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 12, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Official_Bellicum_Logo_RGB.jpg
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
June 28, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
May 17, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
March 04, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
December 11, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...